CTSD and metabolic dysfunction-associated steatohepatitis: To this end, selective effects of respective small-compound CTSD inhibitors obtained in our in vitro experiment strengthens the possibility that these inhibitors may have therapeutic value in treating NASH without causing disturbances of generalized lysosomal CTSD operations.